← FDA DRUG APPROVALS

FDA NDA · NDA021360

SUSTIVA

Sponsor: BRISTOL MYERS SQUIBB

APPLICATION
NDA021360
TYPE
NDA
ORIGINAL APPROVAL
2002-02-01
LATEST ACTION
2023-11-08
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

SUSTIVA · ReferenceDiscontinued
EFAVIRENZ 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL
SUSTIVA · ReferenceDiscontinued
EFAVIRENZ 600MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL

Approval history

2023-11-08Labeling · Supplement 47 · standardLabelAP
2019-10-29Labeling · Supplement 45 · standardLetterAP
2017-10-10Labeling · Supplement 44 · standardLabelAP
2017-01-30Labeling · Supplement 42 · standardLetterAP
2016-10-31Manufacturing (CMC) · Supplement 40 · standardAP
2016-10-12Labeling · Supplement 41 · standardLabelAP
2016-08-31Labeling · Supplement 39 · standardLetterAP
2016-03-31Labeling · Supplement 38 · standardLetterAP
2015-03-27Labeling · Supplement 37 · standardLetterAP
2014-08-14Manufacturing (CMC) · Supplement 36 · standardAP
2014-05-23Labeling · Supplement 35 · standardLetterAP
2014-01-22Manufacturing (CMC) · Supplement 34 · standardAP
2013-07-09Manufacturing (CMC) · Supplement 32 · standardAP
2013-05-02Efficacy · Supplement 31 · priorityLetterAP
2012-08-10Labeling · Supplement 30 · 901 requiredLabelAP
2012-06-22Labeling · Supplement 29 · standardLetterAP
2011-12-19Labeling · Supplement 28 · standardLabelAP
2011-09-26Labeling · Supplement 26 · standardLabelAP
2010-11-30Labeling · Supplement 24 · standardLetterAP
2010-03-31Labeling · Supplement 23 · unknownLetterAP
2009-09-23Labeling · Supplement 21 · standardLabelAP
2009-03-11Labeling · Supplement 18 · standardLetterAP
2008-08-18Labeling · Supplement 19 · standardLabelAP
2008-08-18Labeling · Supplement 17 · standardLetterAP
2007-01-24Labeling · Supplement 16 · standardLabelAP
2006-03-28Labeling · Supplement 14 · standardLabelAP
2005-04-20Labeling · Supplement 13 · standardLabelAP
2004-10-22Labeling · Supplement 9 · standardLabelAP
2004-08-13Efficacy · Supplement 6 · unknownReviewAP
2003-11-13Labeling · Supplement 5 · standardLetterAP
2003-06-10Labeling · Supplement 4 · standardLabelAP
2003-06-10Labeling · Supplement 3 · standardLabelAP
2002-09-20Labeling · Supplement 1 · standardLetterAP
2002-02-01Type 3 - New Dosage Form · Original · standardLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →